中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 42 Issue 8
Aug.  2026
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2026  >  42(8): 1878-1887

Value of Golgi protein 73 in assessing liver fibrosis degree and prognosis of patients with resectable hepatocellular carcinoma

DOI: 10.12449/JCH260820
  • 1.

    Division of Clinical Research，The First Hospital of Jilin University，Changchun 130021，China

  • 2.

    Cancer Center，The First Hospital of Jilin University，Changchun 130021，China

  • 3.

    School of Public Health，Jilin University，Changchun 130021，China

Research funding:

Youth Science Foundation Project (82204116)

More Information
  • Corresponding author: Jiang Jing， jiangjing19702000@jlu.edu.cn （ORCID： 0000-0001-9714-9255）
  • Received Date: 2026-03-17
  • Accepted Date: 2026-04-10
  • Published Date: 2026-08-25
    Abstract
  •   Objective  To assess the performance of preoperative serum Golgi protein 73 （GP73） in diagnosing liver fibrosis degree in patients with resectable hepatocellular carcinoma （HCC）， to investigate its value in predicting postoperative survival， and to provide a basis for risk stratification and individualized decision-making in this population.  Methods  A total of 631 patients with HCC who underwent liver resection at The First Hospital of Jilin University from March 1， 2009 to December 31， 2022 were enrolled. The demographic， pathological， and serological features of the patients were collected， and the serum level of GP73 was measured before surgery. Scheuer score determined by liver biopsy was used as the gold standard for diagnosing liver fibrosis； the Spearman correlation analysis was used to investigate the correlation between GP73 and liver fibrosis； the receiver operating characteristic （ROC） curve and the area under the ROC curve （AUC） were used to assess the value of serum GP73 and compound serological markers in the diagnosis of liver fibrosis， and the Delong test was used for comparison of AUC. With all-cause mortality as the outcome， X-Tile 3.6.1 software was used to determine the optimal cut-off value of GP73； the univariate and multivariate Cox regression analyses were used to identify independent influencing factors for prognosis， and a nomogram model was constructed. Ten-fold cross-validation was used for internal validation； index of concordance （C-index）， integrated discrimination improvement （IDI） index， and net reclassification improvement （NRI） index were calculated； calibration curve and decision curve analysis were used to assess the predictive performance of the model.  Results  The serum level of GP73 was positively correlated with Scheuer liver fibrosis stage （rs =0.255， P<0.001）. Serum GP73 had a significantly higher AUC than gamma-glutamyl transferase-to-platelet ratio （0.704 vs 0.634， Z=2.00， P=0.046） and S index （0.704 vs 0.637， Z=1.98， P=0.048） in the diagnosis of significant liver fibrosis， with no significant difference compared with aspartate aminotransferase-to-platelet ratio index （AUC=0.722） and fibrosis-4 index （AUC=0.695） （both P>0.05）. During a median follow-up time of 48.66 months， 239 patients （37.9%） died. GP73 had an optimal cut-off value of 65 ng/mL in predicting postoperative mortality in patients with resectable HCC， and high GP73 expression （≥65 ng/mL） alone achieved a C-index of 0.617 for predicting the prognosis of HCC patients， which was better than the C-index of 0.551 for Barcelona Clinic Liver Cancer （BCLC） stage （P<0.001）. The multivariate Cox regression analysis showed that serum GP73 （hazard ratio ［HR］=2.56， 95% confidence interval ［CI］： 1.86 — 3.52， P<0.001）， sex （HR=1.58， 95%CI： 1.10 — 2.28， P=0.014）， vascular invasion （HR=1.69， 95%CI： 1.30 — 2.21， P<0.001）， total bilirubin （HR=1.49， 95%CI： 1.16 — 1.93， P=0.002）， and maximum tumor diameter （HR=1.07， 95%CI： 1.04 — 1.11， P<0.001） were independent risk factors for all-cause mortality after hepatectomy in patients with HCC. In order to assess whether the addition of GP73 to the other four variables could further improve model performance， the model based on GP73， sex， vascular invasion， total bilirubin， and maximum tumor diameter was defined as the GP73-included model， and the model based on all five variables except GP73 was defined as the GP73-excluded model. The GP73-included model achieved an AUC of 0.704 （95%CI： 0.656 — 0.753） for predicting 5-year survival rate after surgery， and ten-fold cross-validation showed that this model had a mean C-index of 0.716 （95%CI： 0.682 — 0.750）， which was higher than the C-index of the GP73-excluded model （C-index=0.682， 95%CI： 0.645 — 0.719， P=0.008） and BCLC stage （C-index=0.551， 95%CI： 0.523 — 0.580， P<0.001）. Compared with the GP73-excluded model， the GP73-included model yielded an IDI index of 0.039 （95%CI： 0.016 — 0.069， P<0.001） and an NRI index of 0.259 （95%CI： 0.179 — 0.335， P<0.001）， and compared with BCLC stage， the GP73-included model had an IDI index of 0.112 （95%CI： 0.069 — 0.163， P<0.001） and an NRI index of 0.272 （95%CI： 0.169 — 0.380， P<0.001）. Calibration curve and decision curve analyses showed that the GP73-included model had good calibration and net clinical benefit.  Conclusion  GP73 can be used as a serological biomarker for diagnosing liver fibrosis in patients with resectable HCC， and preoperative GP73 level has a certain value in predicting the survival of these patients after hepatectomy. The integrated prognostic model incorporating GP73 can help to optimize postoperative risk stratification， thereby providing a basis for decision-making in precise treatment of HCC.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74( 3): 229- 263. DOI: 10.3322/caac.21834.
    [2]
    Wang Z X, Qin H J, Liu S, et al. Precision diagnosis of hepatocellular carcinoma[J]. Chin Med J, 2023, 136( 10): 1155- 1165. DOI: 10.1097/CM9.0000000000002641.
    [3]
    Yao L Q, Fan H X, Chen F J, et al. Heterogeneity in prognosis for early-stage hepatocellular carcinoma after hepatectomy: A multicenter analysis of 4, 623 patients across five major staging systems[J]. Eur J Surg Oncol, 2025, 51( 10): 110383. DOI: 10.1016/j.ejso.2025.110383.
    [4]
    Sonohara F, Yamada S, Tanaka N, et al. Comparison of non-invasive liver reserve and fibrosis models: Implications for surgery and prognosis for hepatocellular carcinoma[J]. Hepatol Res, 2019, 49( 11): 1305- 1315. DOI: 10.1111/hepr.13400.
    [5]
    Zhang J W, Zhang L, Yang X B, et al. Liver fibrosis as a predictor of liver failure and outcome following ALPPS among patients with primary liver cancer[J]. Sci Rep, 2024, 14: 15827. DOI: 10.1038/s41598-024-65924-2.
    [6]
    Loomba R, Adams L A. Advances in non-invasive assessment of hepatic fibrosis[J]. Gut, 2020, 69( 7): 1343- 1352. DOI: 10.1136/gutjnl-2018-317593.
    [7]
    Smith A, Baumgartner K, Bositis C. Cirrhosis: Diagnosis and management[J]. Am Fam Physician, 2019, 100( 12): 759- 770.
    [8]
    Lan B, Luo C, Pocha C, et al. Comparison of various liver cancer staging systems in predicting prognosis after initial transcatheter arterial chemoembolization: A retrospective study from China[J]. J Gastrointest Oncol, 2024, 15( 6): 2599- 2612. DOI: 10.21037/jgo-2024-850.
    [9]
    Ke M Y, Wu X N, Zhang Y, et al. Serum GP73 predicts posthepatectomy outcomes in patients with hepatocellular carcinoma[J]. J Transl Med, 2019, 17( 1): 140. DOI: 10.1186/s12967-019-1889-0.
    [10]
    Wang Q, Cui H X, Zhu Y P, et al. Serum Golgi protein 73(GP73) is a diagnostic and prognostic marker of hepatocellular carcinoma[J]. Front Med, 2025, 12: 1571761. DOI: 10.3389/fmed.2025.1571761.
    [11]
    Feng P P, Hu X Y, Zhou S N, et al. Golgi protein 73: The driver of inflammation in the immune and tumor microenvironment[J]. Front Immunol, 2024, 15: 1508034. DOI: 10.3389/fimmu.2024.1508034.
    [12]
    An Xinyu, Qiao Jie, Hu Lingxi, et al. A study on the diagnostic value of GP73 in liver fibrosis among patients with chronic liver disease[J]. Chin J Intern Med, 2023, 62( 1): 49- 53. DOI: 10.3760/cma.j.cn112138-20220514-00371.

    安薪宇, 乔杰, 胡灵溪, 等. GP73对慢性肝病患者肝纤维化诊断价值的研究[J]. 中华内科杂志, 2023, 62( 1): 49- 53. DOI: 10.3760/cma.j.cn112138-20220514-00371.
    [13]
    Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis in integrative medicine practice(2019)[J]. J Clin Hepatol, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.

    中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 7): 1444- 1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
    [14]
    Borcak D, Yesilbag Z, Ozdemir Y E, et al. Assessing liver fibrosis in chronic hepatitis B: Liver biopsy or non-invasive fibrosis markers?[J]. J Clin Med, 2025, 14( 22): 8164. DOI: 10.3390/jcm14228164.
    [15]
    Fan Haina, Ma Yangqing, Sun Xin, et al. Role of serum Golgi protein 73 in the assessment of pathological prognosis and its inflammatory influencing factors for hepatitis B virus-related liver fibrosis[J]. Chin J Hepatol, 2025, 33( 8): 772- 780. DOI: 10.3760/cma.j.cn501113-20240419-00212.

    范海纳, 马杨青, 孙鑫, 等. 血清高尔基体蛋白73对乙型肝炎肝纤维化病理预后的评估作用及其炎症影响因素[J]. 中华肝脏病杂志, 2025, 33( 8): 772- 780. DOI: 10.3760/cma.j.cn501113-20240419-00212.
    [16]
    Ye J Z, Gao X, Huang X, et al. Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma[J]. Research(Wash D C), 2024, 7: 0387. DOI: 10.34133/research.0387.
    [17]
    Liu Y M, Hu X Y, Zhou S N, et al. Golgi protein 73 promotes angiogenesis in hepatocellular carcinoma[J]. Research(Wash D C), 2024, 7: 0425. DOI: 10.34133/research.0425.
    [18]
    Zhang J, Zhang M K, Ma H M, et al. A meta-analysis of the prognostic significance of Golgi protein 73 in hepatocellular carcinoma in Chinese patients[J]. Arch Med Sci, 2020, 16( 5): 1104- 1110. DOI: 10.5114/aoms.2019.83821.
    [19]
    Chen L J, Chang Y J, Chang Y J. Survival predictability between the American joint committee on cancer 8th edition staging system and the Barcelona clinic liver cancer classification in patients with hepatocellular carcinoma[J]. Oncologist, 2021, 26( 3): e445- e453. DOI: 10.1002/onco.13535.
    [20]
    Ren Meng, Yang Yi, Li Ziming, et al. Clinical features and prognosis of hepatocellular carcinoma: A single-center study of 850 cases[J]. J Clin Hepatol, 2024, 40( 10): 2019- 2026. DOI: 10.12449/JCH241015.

    任朦, 杨益, 李紫明, 等. 850例单中心肝细胞癌患者的临床特征与预后分析[J]. 临床肝胆病杂志, 2024, 40( 10): 2019- 2026. DOI: 10.12449/JCH241015.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (13) PDF downloads(0) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return